For the Quarter Ending June 2025
North America
• Levetiracetam Price Index in North America witnessed an upward shift in July 2025 as Levetiracetam (Bulk) spot prices rose from June levels, reflecting elevated import-related expenses and stronger demand sentiment across the U.S. pharmaceutical market.
• Levetiracetam Spot Price for Levetiracetam (Bulk) CFR Los Angeles was USD 29888 in June 2025, and prices trended higher in July as sellers responded to ongoing cost inflation from origin countries.
• Levetiracetam Price Forecast for Q3 2025 suggests a moderately bullish outlook supported by firm downstream demand, persistent high freight rates from Asia, and a weaker U.S. Dollar that is expected to keep import costs elevated.
• Levetiracetam Production Cost Trend continued to tighten as Chinese exporters raised FOB values in response to lower inventories and export quotas, which combined with currency depreciation, inflated the landed cost for U.S. buyers.
• Levetiracetam Demand Outlook remained strong, driven by consistent procurement from formulators producing antiepileptic and neurological drugs, while upbeat manufacturing data and stable prescription activity reinforced buyer confidence.
• Why did the price change in July 2025? Prices increased in July 2025 due to rising export quotations from China, elevated container freight rates to U.S. ports, and stable-to-firm downstream pharmaceutical demand that allowed importers to pass on higher costs..
Europe
• Price Index in Europe (Germany) showed a mild upward movement in July 2025, continuing the positive trend from May and June, as Levetiracetam (Bulk) prices rose slightly due to persistent import cost inflation and firm pharmaceutical demand across the region.
• Levetiracetam Spot Price in June 2025 was USD 29810 for Levetiracetam (Bulk) CFR Los Angeles, and in July, prices in Europe climbed further in response to elevated freight rates from Asia and tightening stock levels at domestic warehouses.
• Price Forecast for Q3 2025 remains cautiously bullish, as steady growth in Germany’s pharmaceutical manufacturing sector and restocking demand from formulation units are expected to uphold strong import interest and price stability.
• Levetiracetam Production Cost Trend continues to show moderate pressure, with Chinese suppliers maintaining higher FOB offers amidst thinning inventories and stronger Asian and European demand. Euro strength against the US Dollar offered only partial relief to buyers.
• Levetiracetam Demand Outlook remains positive, underpinned by increased order volumes from German pharmaceutical plants producing antiepileptic and neurological drugs. Renewed healthcare investment and growing outpatient drug usage also supported rising demand.
• Why did the price change in July 2025? Prices increased in July 2025 across Germany due to a combination of firm demand from pharmaceutical buyers, higher freight charges from Asia, tight inventory levels, and elevated export prices from Asia. The continued recovery in Germany’s manufacturing sector and strong purchasing sentiment contributed to the upward pricing pressure.
APAC
• Levetiracetam Price Index in APAC (China) showed consistent upward movement from April to July 2025, with July continuing the bullish trend due to tightening inventories, reduced output, and sustained international demand.
• Levetiracetam Spot Price in June 2025 for Levetiracetam (Bulk) CFR Los Angeles was USD 29,700, reflecting stable export volumes despite constrained production and ongoing currency headwinds from a weakening US Dollar.
• Levetiracetam Price Forecast for Q3 2025 remains firm, supported by anticipated export growth, limited inventory replenishment, and continued strong demand from overseas pharmaceutical importers—particularly in Southeast Asia and the US.
• Levetiracetam Production Cost Trend in July remained elevated, due to currency pressure (USD depreciation), rising raw material expenses, and higher energy costs during peak summer operations in China, prompting suppliers to adjust pricing upward to protect margins.
• Levetiracetam Demand Outlook in July was optimistic, as downstream demand remained strong across pharmaceutical formulation sectors in both the domestic market and major export destinations. Active restocking and new order inflows continued to support healthy procurement volumes.
• Why did the price change in July 2025? Prices increased in July 2025 due to lower domestic inventories, high raw material and processing costs, and robust export demand. Chinese suppliers faced additional margin pressure from the depreciating US Dollar, prompting upward pricing adjustments. Improved overseas demand—especially from the US and Europe—kept offtake levels strong, further tightening supply and supporting higher prices.
For the Quarter Ending March 2025
North America
The U.S. Levetiracetam (USP) market displayed moderate upward price movement across Q1 2025, with market conditions evolving from exceptional stability in January to a tighter, more cost-sensitive environment by March. January began with a negligible price uptick of just 0.12%, driven by balanced demand, routine procurement, and disciplined production aligned with predictable prescription trends. Stable freight rates and minimal import disruptions reinforced a calm market environment.
However, February brought a pronounced shift. A 10% tariff hike on Chinese imports effective February 4, rising production costs, and intensified demand pushed prices upward. Import-dependent buyers accelerated procurement amid declining inventories and slower deliveries, leading to noticeable price inflation. Increased U.S. manufacturing activity, alongside improved consumer sentiment and a 0.2% CPI rise, added to downstream demand, particularly in the pharmaceutical segment.
In March, prices edged higher once again as Chinese export prices rose and trade uncertainties persisted. The imposition of retaliatory tariffs and constrained supply led to tighter availability and elevated procurement costs. Despite easing inflation, with the CPI easing to 2.4%, buyers adopted precautionary purchasing strategies to secure steady supply. Q1 concluded with a firm pricing outlook, reflecting cumulative effects of tariffs, raw material inflation, and stable-to-strong demand in the pharmaceutical sector.
Asia Pacific
The Asian Levetiracetam (USP) market, led by China, recorded a gradual price increase throughout Q1 2025 amid a tightening supply environment and sustained demand from pharmaceutical sectors. Prices rose modestly by 0.28% in January, reflecting stable output from GMP-compliant facilities and steady demand for pharmacopeia-grade formulations. Despite a dip in China’s Manufacturing PMI to 49.1, strict regulatory compliance and consistent export activity supported the market. Logistics constraints from 28 blanked sailings and extended lead times added minor operational friction, though most suppliers managed inventory effectively to avoid significant disruptions.
February saw a sharper upward pricing trend driven by reduced domestic inventories, rising production costs, and a 10% tariff on Chinese exports to the U.S., effective February 4. Buyers responded with bulk purchases, aiming to hedge against trade volatility. Lower freight costs stimulated international interest, especially from Europe and the U.S., further tightening supply and amplifying pricing momentum.
In March, prices edged higher again amid continued procurement urgency and robust manufacturing activity, as China’s PMI rose to 50.5—its highest in a year. Firm international demand, currency pressures, and constrained raw material availability upheld market strength. Despite easing inflation, the quarter closed with stable-to-firm pricing, shaped by regulatory stringency and resilient downstream demand.
Europe
In Q1 2025, the German Levetiracetam market experienced a steady upward pricing trend, marked by a cumulative series of modest increases driven by stable demand and persistent supply-side challenges. Prices rose by 0.18% in January as German importers advanced procurement ahead of the Lunar New Year, mitigating anticipated supply chain delays. Buyers strategically secured inventories to maintain Q1 continuity, while producers sustained regular output. Although inventory levels remained sufficient, blank sailings and shipping alliance disruptions added pressure to delivery timelines and freight costs.
In February, prices continued to rise due to low inventory levels, strong downstream demand, and a weakened Euro following tariff-related currency depreciation. Elevated prices in China, a key exporter, also pushed up import values. While lower freight costs offered some reprieve, they were outweighed by robust demand and higher origin market pricing. The increase in Germany’s Manufacturing PMI and stable inflation at 2.3% supported consumption, especially in the neurological pharmaceutical segment.
March sustained the upward trajectory, with improved industrial activity and easing inflation (2.2%) maintaining firm demand. However, elevated Chinese export prices and continued euro volatility sustained procurement pressure. Despite freight cost reductions, cumulative upstream and currency-related factors ensured pricing remained moderately elevated throughout the quarter.
For the Quarter Ending December 2024
North America
During Q4 2024, the Levetiracetam market in North America demonstrated consistent stability throughout the quarter. The market maintained balanced conditions driven by steady demand from pharmaceutical manufacturers and well-managed supply chains. Regular procurement patterns persisted as US buyers operated with comfortable inventory positions while maintaining routine buying behaviour.
The quarter witnessed systematic trading activity as pharmaceutical companies engaged in regular procurement amid stable market conditions. Supply chain dynamics remained efficient, with manufacturers maintaining steady price positions supported by balanced production costs and consistent demand patterns. The API sector's sustained requirements, coupled with predictable demand from generic drug manufacturers, contributed to the stable market sentiment.
December saw continued price stability as year-end activities aligned with typical seasonal patterns. Domestic suppliers maintained consistent offers, supported by regular order books and well-managed inventory positions. The market's steadiness was reinforced by predictable consumption patterns and strategic supply management by key manufacturers, maintaining stable price levels through quarter-end.
APAC
In Q4 2024, Levetiracetam prices in APAC markets exhibited remarkable stability throughout the quarter. The market operated with steady fundamentals as producers effectively balanced production rates with demand requirements. Operations continued with stable market sentiment, supported by consistent domestic consumption and regular export inquiries.
Asian manufacturers maintained steady price positions, effectively managing production costs while meeting regular order flows across the quarter. The market witnessed routine trading activity as both domestic and international buyers engaged in systematic procurement. Regional trading patterns remained predictable as suppliers maintained disciplined pricing strategies aligned with stable demand fundamentals.
December brought continued market stability as manufacturers focused on maintaining balanced inventory positions. Several facilities reported steady capacity utilization rates amid regular order flows. The combination of well-managed supply conditions, consistent demand patterns, and strategic inventory management by producers helped maintain stable price levels. Export markets remained active with routine inquiries from international buyers supporting the market's stability.
Europe
In Q4 2024, Levetiracetam prices in Germany reflected the global stability trend. The quarter began with balanced market fundamentals as buyers operated with adequate availability and steady offers from Asian suppliers. European manufacturers maintained stable price positions, supported by regular order flows and controlled production rates.
The steady market conditions continued through November as pharmaceutical sector demand remained consistent. Buyers engaged in routine procurement activities amid comfortable supply conditions and stable production costs. The market witnessed regular trading patterns as distributors maintained typical inventory levels.
December's market dynamics remained unchanged as European distributors maintained balanced positions. The combination of adequate supply availability and consistent demand fundamentals supported stable price levels. While consumption patterns remained steady across pharmaceutical applications, the market's stability persisted through quarter-end, creating a predictable environment for both buyers and sellers.
FAQ’s
Why did Levetiracetam prices increase in China during July 2025?
Levetiracetam prices in China rose in July due to continued production constraints, low inventory levels, and strong demand from both domestic and export markets. Seasonal production slowdowns, combined with a depreciating US Dollar that reduced exporter margins, pushed suppliers to raise prices further. Robust offtake from overseas buyers, especially in the US and Southeast Asia, added to the upward pressure.
What factors influenced the Levetiracetam (Bulk) CFR Los Angeles price of USD 29,700 in June 2025?
The CFR Los Angeles price reflected tightened Chinese supply and healthy US import demand. Prices remained high due to reduced Chinese output, elevated production costs, and international buyers securing volumes amid currency-related pricing volatility. Trade sentiment was also supported by the easing of logistical hurdles and improved order flow from major US pharmaceutical buyers.
How did the US market respond to the rising Levetiracetam prices from China in Q2 2025?
US buyers responded by front-loading purchases during April and May to mitigate risk from expected price increases. Although the June CFR Los Angeles price was already elevated at USD 29,700, US demand remained strong due to stable downstream formulation requirements and limited alternative sourcing options, keeping overall price levels firm through July.
What is the price outlook for Levetiracetam in APAC for August 2025?
The price outlook for APAC (particularly China) remains firm for August 2025, supported by persistently low inventories, steady domestic consumption, and rising export commitments. Suppliers are expected to maintain elevated offers, especially if production does not normalize and currency-driven margin pressures persist.
Are Levetiracetam prices decreasing in any region as of July 2025?
No significant price declines were observed across key markets (APAC, North America, or Europe) in July 2025. Instead, all regions reflected either steady or increasing prices. In Europe, stable procurement from hospital chains and pharmaceutical distributors supported moderate price resilience, while Southeast Asian buyers relied heavily on Chinese exports amid limited regional manufacturing, contributing to sustained upward momentum.
